profit from every $100 of sales.
$0$100
DRI Healthcare
$13.65+0.89% today
+27.5% in 1 year
1-year low $10.701-year high $13.90
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
DRI Healthcare vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| DRI Healthcare | No profit yet | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads DRI Healthcare's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 1.6×
- 4.9×
- 34.2×
- –
- 2.9%
- -6.7%
- –
Profitability
- –
- –
- -32.9%
- –
- –
- –
- –
- –
- –
- –
Growth
- +24.3%
- –
- –
- –
- +13.0%
Financial health
- –
- 0.86
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 23%of 870
Top 36%of 985
News
Gabelli Healthcare & Wellness Trust raises dividend by 17.6% to $0.20Seeking Alpha · Nov 11, 2026Healthcare Just Hit a Record Lead Over Tech. 3 Things Could Shrink ItYahoo Finance · Nov 11, 2026Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focusSeeking Alpha · Nov 8, 2026The Healthcare ETF Showdown: Broad Global Health or Targeted Pharma Power?Yahoo Finance · Nov 7, 2026American Healthcare REIT forecasts $2.23-$2.26 2026 NFFO per share as same-store NOI growth target rises to 12%-14%Seeking Alpha · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about DRI Healthcare
Is DRI Healthcare a good stock to buy?
A business with weak numbers that is not profitable yet. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the DRI Healthcare AI analysis
What does DRI Healthcare do?
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. It is in Drug Manufacturers - Specialty & Generic.
Is DRI Healthcare stock halal?
No. DRI Healthcare does not pass our halal screen: its debt is 50% of its market value, at or above the 33% limit. How we check
How has DRI Healthcare stock done over the past year?
Up 27.5% over the past twelve months, to $13.65. It traded between $10.70 and $13.90, close to its high.
Who are DRI Healthcare's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with DRI Healthcare's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.